Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

Hyperfine, Inc.

HYPRNASDAQ
Wall Street Score · overall investment25/100
$0.78USD+$0.03 (+4.66%)

Severe listing-compliance risk

The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.

Company website www.hyperfinemri.com
Headquarters351 New Whitfield Street, Guilford, CT, 06437, US
Financial statement currencyUSD · no FX conversion applied
Healthcare · Medical - Devices
Price updated todayFinancials updated Oct 1, 2026

HYPR · Price history

Price at last available close

$0.78

−$0.02 (-2.53%) 1M

2026-10-28

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Company & revenue

About Hyperfine, Inc.

Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.

Who they are

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system.

How they make money

Hyperfine generates revenue primarily through the sale of its Swoop portable MRI systems and associated service contracts. The company also derives income from the licensing and sale of its proprietary Optive AI software, which enhances image quality and scanner usability for healthcare providers in hospital and neurology office settings.

Products & services

The Swoop system is an FDA-cleared, AI-powered portable magnetic resonance imaging (MRI) device designed for brain imaging. It is complemented by Optive AI software, which improves image resolution and uniformity.

Brands & revenue mix

Swoop

The company's primary portable MRI brain imaging system.

Separate brand revenue is not available in this research.Source

Optive AI

Software suite designed to enhance image resolution and scanner usability.

Separate brand revenue is not available in this research.Source

Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.

Product / operating segments

ProductUSD 11.40M84.0%

Period ended 2025-12-31Source

ServiceUSD 2.17M16.0%

Period ended 2025-12-31Source

Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.

Geographic revenue

No reconciled geographic revenue breakdown was confirmed for the current research period.

Customer types

Customer concentration

As of the period ended September 30, 2025, the company reported that one customer accounted for 10% or more of total net revenue for the nine-month period.

Suppliers, materials & equipment

  • Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its Swoop system components; the specific supplier names are unnamed.Source

Competitors

  • General Electric Company — Competes in the broader medical imaging and MRI market.Source
  • Siemens Healthineers AG — Competes in the broader medical imaging and MRI market.Source
  • Koninklijke Philips N.V. — Competes in the broader medical imaging and MRI market.Source

Strengths

  • Proprietary ultra-low-field magnet technologySource
  • User-friendly interface requiring minimal trainingSource

Risks

  • Dependence on third-party manufacturersSource
  • Regulatory approval and compliance requirementsSource

Financial risk observations and what to check

These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.

Diluted weighted-average shares increased 27.8% year over year.

Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.

Total debt increased 5535.7% versus the same quarter last year.

Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.

Wall Street Score

Overall investment score · Quality, value, risk and opportunity

25

Poor

PoorElite

View category scores →

Company Quality

How good is the actual business—regardless of today’s stock price?

36

Poor

Financial Strength

27

Business Quality / Moat

33

Management

40

Growth Quality

61

Risk / Durability

26

Weak Company · Expensive Stock

Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.

Opportunity

Opportunity Score · How does the current price compare with estimated value?

34

Avoid

Based on current valuation, company quality, recent trends, and available market signals.

View score details →

Model Outlook

12-month model · What does the model think happens next?

47/100

Building Historical Record

Model Score 47/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.

Probability unavailable — the model has not produced a calibrated probability yet.

Click for full breakdown →

Reverse-split / listing-compliance risk: HIGH

This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.

Risk indicator: 55/100

WSS View

The quick read

The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.

At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.

The model outlook is currently cautious.

What we like

No strong positive signal is being highlighted from the currently available summary data.

What to watch
  • •Valuation is a weaker part of the current profile
  • •Revenue fundamentals are weak
  • •Debt / balance-sheet profile needs attention
  • •Asset quality is a weaker factor

Company-specific research

Questions worth answering for HYPR

Research inputs 100% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •Can HYPR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • •How long can HYPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • •How is HYPR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • •What specifically needs to improve for HYPR to reach sustainable profitability?
  • •What future growth or profitability would be needed to justify HYPR's current valuation?
Business analysis: 16 days ago · Fresh

Essential Investment Snapshot

Wall Street Score

25

0–100 · Poor

Opportunity Score

34

0–100 · Poor

Market Cap

$71.4M

P/E Ratio

-2.1

EPS

$-0.38

52-Week High

$2.22

52-Week Low

$0.75

Beta

1.41

Analyst Target

$2.00

Shares Outstanding

94.2M

Total Revenue

$16.5M

Total Debt

$13.4M

Dividend

No current dividend

View dividend history

Liquidation Value / Share

$0.39

Estimated net asset value per share

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
38/ 100
+15 pts / 5d

Weakening momentum

5D +5.1% · 20D -2.9% · RSI 26 · Price vs 20D avg -3.9%
Volatility
66/ 100
+3 pts / 5d

Elevated movement

20D realized vol 67.5% · 60D 48.4% · Acceleration 1.39x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on HYPR.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Proprietary ultra-low-field magnet technology.
  • +User-friendly interface requiring minimal training.

Potential downside factors

  • −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
  • −Dependence on third-party manufacturers.
  • −Regulatory approval and compliance requirements.
  • −Diluted weighted-average shares increased 27.8% year over year.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown
Wall Street Score
Very Weak25/ 100
Weak (0–50)Fair (51–71)Strong (72+)

Poor

25

Tap for breakdown →

Poor

34

Debt Cost—
Debt Reduction YoY-16.7%
Debt / Equity0.01x

Tap for breakdown →

Poor

28

Revenue YoY21.9%
Revenue CAGR10.9%
Net Margin-210.8%

Tap for breakdown →

Poor

38

Asset Growth YoY-6.2%
Liquidation/Share$0.39
Net Assets/MCap0.73x

Tap for breakdown →

Poor

0

Earnings Yield-51.2%
Buyback Yield0.0%
Debt Cost—

Tap for breakdown →

Weak

40

ROIC-552.4%
ROE-94.8%
ROA-55.3%

Tap for breakdown →

Poor

33

EPS Growth—
FCF/Share Growth—
Rev/Share Growth20.1%

Tap for breakdown →

Poor

0

Intrinsic Value—
Value Reference—
MOS—

Tap for breakdown →

Poor

31

Revenue28
Moat33
Valuation0

Tap for breakdown →

Poor

0

MOS %—
Value Reference—
Deep Discount Reference—

Tap for breakdown →

Poor

32

Interest Coverage—
ROIC-552.4%
FCF Yield-42.8%

Tap for breakdown →

Poor

26

Financial32
Valuation0
Debt34

Tap for breakdown →

Fair

60

Survival Years1.2 yrs
Current Ratio4.34x
FCF Margin-214.8%

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

3 historical score records available

Previous Score

25

Aug 14, 2026

Change

+0.3

points

Current Score

25

Oct 1, 2026

Category Changes

Revenue+0.2
Debt0
Assets+2.2
Capital0
Management0
Moat0
Valuation0
Buffett+0.3

HYPR increased 0.3 points because Asset improved by 2.2 points.

Positive Contributors

  • + Asset improved by 2.2 points

Projected Score

Projected Score

26

Projected Change

+0.8 points

Preliminary comparable-period financial changes suggest improvement of approximately 0.8 points. This is a projected estimate, not the official WallStreetScore.

Price vs. Value

Valuation unavailable

Current Price

$0.78

Model Intrinsic Value

—

Difference

—

Margin of Safety

—

Value Reference: —
Deep Discount Reference: —

Intrinsic value is not currently available for this stock, so valuation can't be calculated.

Financial Charts

Revenue

2019202020212022202320242025$0$4M$7M$11M$14M

Additional Metrics

Operating Cash Flow

2019202020212022202320242025-$75M-$60M-$45M-$30M-$15M

Total Debt

2019202020212022202320242025$0$80000$160000$240000$320000

Total Assets

2019202020212022202320242025$0$55M$110M$165M$220M

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line ItemTTM2025202420232022202120202019
Revenue$16.5M$13.6M$12.9M$11.0M················
Cost of Revenue$8.0M$6.8M$7.0M$6.3M················
Gross Profit$8.5M$6.8M$5.9M$4.8M················
Research & Development$15.6M$17.5M$22.5M$22.5M················
SG&A Expenses$26.5M$26.4M$26.6M$30.4M················
Operating Expenses$42.1M$43.8M$49.1M$52.9M················
EBITDA-$32.4M-$33.4M-$39.7M-$43.2M················
Operating Income-$33.6M-$37.1M-$43.2M-$48.1M················
Interest Expense$616K$0.00$0.00$0.00················
Income Before Tax-$34.9M-$35.6M-$40.7M-$44.2M················
Income Tax Expense$0.00$0.00$0.00$0.00················
Net Income-$34.9M-$35.6M-$40.7M-$44.2M················
Basic EPS$-0.38$-0.43$-0.56$-0.62················
Basic Shares99.80M94.20M72.41M71.32M················
Diluted Shares99.80M94.20M72.41M71.32M················
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Nov 12, 2026
Estimated EPS: -$0.08Estimated revenue: $5.1M
Jun 30, 2026Q2FY2026

Revenue

$3.9M

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

-$0.09

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

+5535.7%

Cash Change

+71.0%

Margin Change

+104.0 pp

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Margins expanded
  • Cash position grew

What Weakened

  • Debt increased

Potential Score Impact

Positive indicators included revenue growth, cash levels, net income margin. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

Revenue increased 44.8%. EPS declined 25.0%. Cash increased 71.0%. Total debt increased 5535.7%. Net income margin improved by 104.0 percentage points.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Upgrade to Premium to unlock all earnings history.View plans
Earnings data: 121 days ago · Stale

Insider Activity

Guru / Smart Money

Guru Score

Smart Money

Number of Gurus

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Loading data...

Short Interest

Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Dividend data is not available yet. Missing data does not mean this company pays no dividend.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

3 historical records
Jul 23, 26Aug 14, 26Oct 1, 260255075100

Historical Score Chart

3 of 3 records shown

Wall Street Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Debt Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Revenue Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Asset Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Capital Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Management Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Moat Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Valuation Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Buffett Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Intrinsic Value

No data

Value Reference

No data

Margin of Safety %

No data

Related Companies

Medical - Devices

INSP

Inspire Medical Systems, Inc.

64Fair
$71.30View

GMED

Globus Medical, Inc.

64Fair
$81.26View

TMDX

TransMedics Group, Inc.

60Fair
$69.73View

SNN

Smith & Nephew plc

60Fair
$30.12View

ELMD

Electromed, Inc.

59Fair
$26.62View

PODD

Insulet Corp.

58Fair
$148.93View

News

Rumor Mill · HYPR

Corporate developments & opportunities

Explore market →

No reviewed developments match this filter.

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksStocks under $10Best growth stocksBest healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial health

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial